For the month ended 31 March 2026, Suzhou Ribo Life Science Co., Ltd. (RIBOLIFE-B) reported no changes in its authorised, registered or issued share capital. Authorised and issued ordinary H-shares closed the period unchanged at 170.55 million shares, each with a par value of RMB 1, translating into total authorised and issued share capital of RMB 170.55 million.

\n\nThe company confirmed full compliance with Hong Kong Main Board Rule 13.32D(1) regarding minimum public float. The public float threshold—set at 15.61% of issued H-shares at listing—remained satisfied as of 31 March 2026.

\n\nShare-based incentives under the Pre-IPO Share Option Scheme were unchanged. A total of 2.11 million options, carrying an exercise price of RMB 3.70 per share, remained outstanding with no vesting or exercises during the month. The earliest vesting date is 9 January 2028.

\n\nThere were no share repurchases, treasury-share movements, warrant issues, convertible securities, or other equity-related arrangements in March 2026.